<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03325504</url>
  </required_header>
  <id_info>
    <org_study_id>ORTHOUNION</org_study_id>
    <secondary_id>2015-000431-32</secondary_id>
    <secondary_id>EUCTR2015-000431-32-ES</secondary_id>
    <nct_id>NCT03325504</nct_id>
  </id_info>
  <brief_title>A Comparative Study of 2 Doses of BM Autologous H-MSC+Biomaterial vs Iliac Crest AutoGraft for Bone Healing in Non-Union</brief_title>
  <acronym>ORTHOUNION</acronym>
  <official_title>A Multi-centre, Open-label, Randomized, Comparative Clinical Trial of Two Doses of Bone Marrow Autologous MSC+ Biomaterial vs Iliac Crest Autologous Graft, for Bone Healing in Non-union After Long Bone Fractures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidad Autonoma de Madrid</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universidad Autonoma de Madrid</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      ORTHOUNION is a multi-centre, open, comparative, randomized, clinical trial with three&#xD;
      parallel arms that aims to compare the efficacy of three treatments to enhance bone healing&#xD;
      in patients with long bone non-union.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Bone injuries represent an important world medical problem producing significant healthcare&#xD;
      and societal expenditure. While most bone injuries are not severe and are capable of healing&#xD;
      through bone regeneration by natural callus formation with standard treatments, severe bone&#xD;
      injuries may not heal, becoming an important unmet clinical need.&#xD;
&#xD;
      Non-unions, or pseudarthrosis, may occur in 5% to 20% of long-bone fractures that fail to&#xD;
      heal properly after more than 6 months, with morbidity, prolonged hospitalization, and&#xD;
      increased expenses. The most commonly accepted standard augmentation to procure fracture and&#xD;
      non-union healing consists of autologous bone grafting, obtained from the same patient in a&#xD;
      different surgical site and transplanted to the reconstruction site. However, autologous bone&#xD;
      grafting has some drawbacks (such as persistent pain, scar, late recovery, limited amount of&#xD;
      bone, etc) and a limited regeneration efficacy (success rate of about 74%) and high societal&#xD;
      cost. Culture-expanded autologous MSCs combined with biphasic calcium phosphate (BCP)&#xD;
      biomaterial granules have been claimed as a solid regenerative medicine alternative to&#xD;
      autologous bone grafting in non-unions, although current data are limited. In this context,&#xD;
      the ORTHOUNION initiative focuses on the opportunity to test the hypothesis of superiority of&#xD;
      MSC, the investigational ATMP, versus the currently accepted standard therapy, iliac crest&#xD;
      bone autograft to biologically augment surgical treatment of long-bone non-unions.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 5, 2017</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Actual">June 30, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bone consolidation</measure>
    <time_frame>12 months after treatment</time_frame>
    <description>The percentage of bone consolidation in the comparator treatment arm ( iliac crest autograft) and experimental treatment arm (mesenchymal cells).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bone consolidation</measure>
    <time_frame>6 and 24 months</time_frame>
    <description>To compare bone consolidation between the experimental arms and the comparator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiological Bone consolidation</measure>
    <time_frame>6, 12 and 24 months</time_frame>
    <description>To compare bone consolidation, using the REBORNE scale, between the experimental arms and the comparator.&#xD;
The REBORNE scale is an ad-hoc and validated scale, developed by Gomez Barrena et al. (article currently under preparation) as a modification of the RUST score (Whelan, 2010; Journal of Trauma). In the REBORNE scale, the presence/absence of radiological consolidation is evaluated on a total of 4 cortices. Score range from 0 (no bone callus visible) to 4 (callus present with same density as cortical). The total score will be recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of Pain</measure>
    <time_frame>6, 12 and 24 months</time_frame>
    <description>To compare level of pain (by Numeric Rating Scale [NSR]) between the experimental arms and the comparator.&#xD;
The NRS is a scale that rates the patient´s pain from 0-10 (0= no pain, 10= worst pain), at the time of the visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications</measure>
    <time_frame>6, 12 and 24 months</time_frame>
    <description>To compare the rate of complications between the experimental arms and the comparator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health status</measure>
    <time_frame>6, 12 and 24 months</time_frame>
    <description>To compare the health status (by using the Short Form-36 Health Questionnarie) between treatment arms.&#xD;
The SF-36 questionnaire is a validated, widely used patient-reported health survey which measures their physical and mental health status. It consists of 36 questions organized in 8 dimensions. The total score will be recorded.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Non Union Fracture</condition>
  <arm_group>
    <arm_group_label>hBM-MSCs-Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Autologous Cultured Mesenchymal Stem Cells +Biomaterial (Low Dose): 100x106 cells</description>
  </arm_group>
  <arm_group>
    <arm_group_label>hBM-MSCs-High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Autologous Cultured Mesenchymal Stem Cells+Biomaterial (High Dose): 200x106 cells</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Autologous Illiac crest graft</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Autologous Iliac Crest Grafting</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cultured Mesenchymal Stem Cells</intervention_name>
    <description>Cultured Mesenchymal Stem Cells obtained from expanded bone marrow</description>
    <arm_group_label>hBM-MSCs-High Dose</arm_group_label>
    <arm_group_label>hBM-MSCs-Low Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Autologous iliac crest graft</intervention_name>
    <description>Autologous iliac crest grafting</description>
    <arm_group_label>Autologous Illiac crest graft</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18 years and older, both sexes&#xD;
&#xD;
          2. Traumatic isolated closed or open Gustilo I and II, IIIA and IIIB humerus, tibial or&#xD;
             femur diaphyseal or metaphysodiaphyseal fracture with a status of atrophic,&#xD;
             oligotrophic or normotrophic non-union.&#xD;
&#xD;
          3. Able to understand, accept and sign informed consent&#xD;
&#xD;
          4. Medical health coverage&#xD;
&#xD;
          5. Able to understand and accept the study constraints&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Hypertrophic non-unions&#xD;
&#xD;
          2. Segmental bone loss requiring specific therapy (bone transport, vascularized graft,&#xD;
             large structural allograft, megaprosthesis, etc)&#xD;
&#xD;
          3. Unrecovered vascular or neural injury&#xD;
&#xD;
          4. Other fractures causing interference with weight bearing&#xD;
&#xD;
          5. Visceral injuries or diseases interfering with callus formation (severe&#xD;
             cranioencephalic trauma, etc.)&#xD;
&#xD;
          6. Active infection of any location and aetiology&#xD;
&#xD;
          7. Surgical contraindication of any cause&#xD;
&#xD;
          8. Pregnancy, breast feeding women and women who are of childbearing age and not&#xD;
             practicing adequate birth control.&#xD;
&#xD;
          9. Malignant tumour (past history or concurrent disease)(except carcinoma in situ or&#xD;
             basalioma in remission)&#xD;
&#xD;
         10. History of bone harvesting on iliac crest contraindicating new iliac crest bone graft&#xD;
             harvesting or bone marrow collection&#xD;
&#xD;
         11. Insulin dependent diabetes&#xD;
&#xD;
         12. Any evidence (confirmed by PCR) of active infection with HIV, Hepatitis B or Hepatitis&#xD;
             C infection&#xD;
&#xD;
         13. Any evidence of Syphilis&#xD;
&#xD;
         14. Known allergies to products involved in the production process of MSC&#xD;
&#xD;
         15. Corticoid or immunosuppressive therapy more than one week in the three months prior to&#xD;
             study inclusion&#xD;
&#xD;
         16. Autoimmune inflammatory disease&#xD;
&#xD;
         17. Current treatment by biphosphonates not stopped three months prior to study inclusion&#xD;
&#xD;
         18. Impossibility to meet at the appointments for the follow up&#xD;
&#xD;
         19. Participation in another therapeutic trial in the previous 3 months&#xD;
&#xD;
         20. Second non-union in case of bilateral or multiple non-unions (only one non-union per&#xD;
             patient will be included in the trial)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Enrique Gomez-Barrena, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>UAM</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Orthopaedic Surgery, Hospital Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Orthopaedic Surgery, CHU Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Orthopaedic Surgery Toulouse University Hospital</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Orthopaedic Surgery, CHU Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Frankfurt, Department of Trauma, Hand and Reconstructive Surgery</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Freiburg, Klinik für Orthopädie und Unfallchirurgie</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum München</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Orthopaedic Trauma, University of Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>8907581</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Ortopedico Rizzoli, SSD Fisiopatologia Ortopedica e Medicina Rigenerativa</name>
      <address>
        <city>Bologna</city>
        <zip>40136</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arienda Spedali Civili di Brescia II Ortopedia e Traumatologia</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Ortopedico Galeazzi, Chirugia dell´Anca l</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero- Universitaria di Modena, Reparto di Ortopedia e Traumatologia</name>
      <address>
        <city>Modena</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Universitaria Ospedaliera di Pisa- II, Clinica di Ortopedia e Traumatologia</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital U. Puerta de Hierro-Majadahonda, Servicio de Cirugía Ortopédica y Traumatología</name>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínica San Carlos, Servicio de Cirugía Ortopédica y Traumatología</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital U. 12 de Octubre, Servicio de Cirugía Ortopédica y Traumatología</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital U. Gregorio Marañon, Servicio de Cirugía Ortopédica y Traumatología</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital U. La Princesa, Servicio de CirugíaOrtopédica y Traumatología</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Servicio de Cirugía Ortopédica y Traumatología &quot;A&quot;, Hospital La Paz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://orthounion.eu</url>
    <description>Webpage of the Orthounion Study</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 25, 2017</study_first_submitted>
  <study_first_submitted_qc>October 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 30, 2017</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidad Autonoma de Madrid</investigator_affiliation>
    <investigator_full_name>Prof Enrique Gomez-Barrena</investigator_full_name>
    <investigator_title>Full Professor and Chair of orthopaedic surgery</investigator_title>
  </responsible_party>
  <keyword>Non-union</keyword>
  <keyword>Advanced therapies</keyword>
  <keyword>Mesenchymal stem cells</keyword>
  <keyword>Long bone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fractures, Ununited</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

